Solara Active Pharma Sciences Ltd. · NSE:SOLARA
Solara Active Pharma Sciences — Q4 FY2018 Earnings Presentation
8 slides from Solara Active Pharma Sciences's earnings presentation, May 2018
Slide 1: Pure play APIs. Q4 FY18 Performance review
Pure play APIs. SOLARA ACTIVE PHARMA SCIENCES Q4 FY18 Performance review | May 2018 1
Slide 2: Solara Today
Solara Today API only business model with large scale infrastructure, wide products and established customer relationships Capabilities Research Complex chemistry capabilities including Pipeline of 20+ products under handling of catalytic hydrogenation, hydride different stages of development reduct
Slide 3: Key Highlights for Q4FY18 and FY18
Key Highlights for Q4FY18 and FY18 “ Q4 Financial Performance FY18 Financial Performance Operational Developments • Net Revenues at ₹3,043mn, • Net Revenues at ₹11,214mn , • New R&D centre set up in registering a growth of 17.7% registering a growth of 18.5% Bangalore completed and Quarter on Quarte
Slide 4: Q4FY18 Performance
Q4FY18 Performance Q4FY18 Review QoQ Trend Particulars Q4 FY18 Q3 FY18 Change Revenues Operating EBITDA EBITDA Revenue 3,042 2,584 17.7% 3003 3042 Operating EBITDA 457 240 90.9% 2587 2584 Operating EBITDA Margins 15.0% 9.3% R&D Cost (27) (53) -49.5% Exchange gain/(loss) (47) 47 -200.3% 382 401 458 4
Slide 5: FY18 Performance
FY18 Performance Q4FY18 Review Key Balance Items Particulars FY18 Proforma FY17 Proforma Change Balance sheet items Value in ₹m Shareholders' funds 7,640 Revenue 11,215 9,463 18.5% Less: Goodwill -3,634 Operating EBITDA 1,537 1,186 29.6% Networth 4,006 Operating EBITDA Margins 13.7% 12.5% Term Loan
Slide 6: Consolidated FY18 Income Statement
Consolidated FY18 Income Statement Q4 FY18 Q3 FY18 FY18 FY17 PARTICULARS Audited Unaudited Proforma Proforma Revenue 3,042 2,584 11,214 9,463 Material Consumption (1,550) (1,384) (5,794) (5,029) Gross Margin 1,492 1,200 5,420 4,434 % 49.1% 46.4% 48.3% 46.9% Operating Expenses (1,035) (960) (3,883) (
Slide 7: Solara - 5 years perspective
Solara- 5 years perspective Business Continuity Portfolio of new products and new customers to augment current base and enable steady growth Worldwide Presence Strive to be amongst the Top Established strongholds in key regulated markets and growth territories 10 pure play Global Active Pharmaceutic
Slide 8: Thank You
THANK YOU. www.solara.co.in 8
Solara Active Pharma Sciences — Q4 FY2018 Earnings Presentation on 6ix